PharmD Info

A forum for Indian Pharmacy Professionals

Important: Registered today to have the complete access on this forum --- Register Here
Information for consumers and health professionals on new drug warnings and other safety information, drug label changes, and shortages of medically necessary drug products. Eg: CDCSO,PvPI and FDA Safety Alerts.
  • User avatar
#2272
U.S. Food and Drug Administration (FDA) is requiring safety labeling changes for methadone and buprenorphine products when used by pregnant women for medication-assisted treatment (MAT) of opioid use disorder to ensure providers have complete information about the benefits and risks of these products. World Health Organization, recommend that pregnant women with opioid addiction be treated with methadone or buprenorphine. According to these guidelines, the rationale for MAT during pregnancy is to prevent complications of opioid abuse, addiction and withdrawal, and encourage prenatal care and drug treatment.

Methadone and buprenorphine can be used for the treatment of pain and/or MAT, which combines medication with counseling and behavioral therapies. MAT plays an important role in treating opioid use disorder. For pregnant women, this treatment may ultimately improve outcomes for them and their babies.

However, MAT can also present challenges due to the risk of the developing fetus being exposed to opioids, which can lead to neonatal opioid withdrawal syndrome (NOWS). NOWS can be effectively managed, but may be life-threatening if not recognized and treated.

Since NOWS can result from in utero exposure to opioids – whether medically authorized or illicit – the risk of NOWS from MAT must be balanced against the risk of untreated opioid addiction during pregnancy; an independent advisory committee and numerous reproductive health experts agree this balance is important. If left untreated, illicit opioid use is associated with poor pregnancy outcomes such as low birth weight, preterm birth, or fetal death.

The FDA’s action requiring safety labeling changes for MAT-only methadone and buprenorphine products is intended to appropriately inform prescribers about the risks of NOWS without inadvertently discouraging treatment for pregnant women with opioid addiction.

This action is among a number of steps the agency has taken recently to inform prescribers about the appropriate use of opioid medications. Labels for buprenorphine products that are used to treat pain are already required to provide information to prescribers about the risks associated with NOWS in a boxed warning, which is the FDA’s strongest warning. These new safety labeling change requirements for methadone and buprenorphine products that are used for MAT include a statement in the Warnings and Precautions section about the risk of NOWS, as well as related modifications to the Pregnancy, Dependence, and Patient Counseling Information sections. (A boxed warning for NOWS is not being required for the MAT-only methadone and buprenorphine products.)

Refrenence: Drug Safety Alerts FDA /Dated [5/26/16]
Similar Topics
Topics Statistics Last post
0 Replies 
1228 Views
by Admin
26 Oct 2018, 06:56
0 Replies 
312 Views
by rahmatulla.syed
10 Feb 2018, 22:36
Taxonomy of Medication Errors
by Admin  - 16 Oct 2018, 11:39  - In: Pharmaceutical Care
0 Replies 
4 Views
by Admin
16 Oct 2018, 11:39
Medication Adherence Apps- Which one is best?
by Admin  - 16 Sep 2017, 13:16  - In: Pharm D Topics
0 Replies 
935 Views
by Admin
16 Sep 2017, 13:16
2 Replies 
1244 Views
by Admin
31 Jan 2017, 11:38

Tags

PharmD Info Online Group Discussion Disc[…]

PCI chalks out plans to allay concerns of educatio[…]

NAAC is in the process of developing a Manual for […]

Telangana Pharmacy Council Renewal Online Link h[…]

WELCOME TO OUR E-LEARN COURSE WORK MODULES